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SUMMARY 
Introduction: The prevalence of Methicillin Resistant Staphylococcus aureus  (MRSA) in Africa is sparsely docu-
mented. In Zimbabwe there is no routine patient or specimen screening for MRSA. The aim of this study was to 
document the presence and epidemiology of MRSA in Zimbabwe. 
Method: The study was done in one private sector laboratory with a national network that serves both public and 
private hospitals. The sample population included in-patients and outpatients, all ages, both genders, all races and 
only one positive specimen per patient was counted. Specimens testing positive for Staphylococcus  aureus  in this 
laboratory were further tested for MRSA using cefoxitin, by standard laboratory procedures. Data was collected 
from 1st June 2013 to 31st May 2014. 
Results: MRSA was positive in 30 of 407 [7.0%] cases of Stapylococcus aureus reported from the laboratory. All 
age groups were affected from neonates to geriatrics. All specimens had similar antibiotic susceptibility pattern. 
Resistance was high for most widely used drugs in Zimbabwe with high sensitivity to vancomycin, linezolid and 
teicoplanin. 
Conclusion: Although there are no recent reports in the literature of the presence of MRSA in Zimbabwe, this study 
documented a 7.0% prevalence. Resistance to common antibiotics is high and antibiotic oversight is required to con-
trol the emergence of resistance to these few expensive drugs. 
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INTRODUCTION 
The prevalence of Methicillin Resistant Staphylococcus 
aureus  (MRSA) in Africa is sparsely documented. In 
Southern Africa only South Africa has reliable data on 
MRSA documented over a long period of time.1,2 Fur-
ther to the north occasional studies have been done in 
West Africa.3,4 The prevalence, antibiotic susceptibility 
and genotypes of MRSA in Europe and North America 
are well characterised due to surveillance.5  In Zimba-
bwe there is no routine patient or specimen screening 
for MRSA. There are no local guidelines or protocols 
for the management of MRSA colonised or infected 
patients. Literature in Zimbabwe on MRSA in humans 
is not recent although there is literature on veterinary 
products (pork and chicken meats).6 The aim of this 
study was to document the presence and epidemiology 
of MRSA in Zimbabwe. 
 
Staphylococcus aureus is a Gram-positive coccus and is 
part of the normal flora in the nose of 10-30% of indi-
viduals. MRSA, is a type of Staphylococcus aureus   
that is resistant to the antibiotic methicillin and other 
drugs in this class like penicillin, oxacillin, amoxicillin. 
It was first described in the UK in 1961 following the 
introduction of the semi-synthetic methicillin in 1959 to 
treat penicillin-resistant Staphylococcus aureus . MRSA 
was commonly isolated in hospital adult patients with 
open wounds, and with medical devices such as in-
dwellings catheters and renal dialysis patients. The 
prevalence of MRSA in the UK was 2.4% in 1975, and 
had risen to peaks of 29% in 1990 before declining to 
19% in 2009.7,8 
 
MRSA develops resistance in a number of ways, but 
key is the possession of an extra mecA gene.  The 
Staphylococcus aureus coat is made of peptidoglycan 
held together in cross-link by peptide chains. Penicillin 
Binding Protein (PBP) is the peptidase that forms the 
cross-link chains.  
In sensitive organisms this is inhibited by β-lactams, 
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resulting in bacteriolysis. In resistant Staphylococcus 
aureus organisms, a different PBP is produced [PBP2A] 
whose affinity for β-lactams is altered while its pepti-
dase activity is not.  
 
This altered PBP is the result of a mecA gene which 
confers resistance by producing an alternative PBP 
when a β-lactam drug is present.  The mecA gene is in-
serted into the MRSA chromosome.  In addition, within 
the cytoplasm, a ‘free floating generic element’ is found 
which contains the same mecA gene and a variety of 
other genes for drug resistance and the ability to be in-
tegrated and excised from the chromosome (ccr). This is 
the SCCmec [Staphylococcal cassette mec]. There are 
MRSA Types I to VIII depending on the combination of 
mec and ccr genes.7,9,10 
 
Table 1 Virulence factors for Staphylococcus  aureus. 
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It is believed that Staphylococcus aureus acquired the 
SCCmec  from other microbes at several different times 
and into several different genetic types since antibiotics 
came into use. The current SCCmec Types are the evo-
lutionary survivors under antibiotic pressure. Whereas 
the earliest MRSA developed in the hospital setting 
(HA-MRSA), methicillin sensitive Staphylococcus au-
reus  (MSSA) in the community also acquired re-
sistance. This became known as community acquired 
MRSA (CA-MRSA). Although the CA-MRSA re-
mained sensitive to a wide range of antimicrobials, this 
has diminished over time, so that currently that differ-
ence is disappearing.11,12 
 
At the same time Staphylococcus aureus, which causes 
mostly superficial abscesses and cellulitis, can cause 
serious illness when it becomes systemic.[Table 1] This 
can be facilitated by break in the skin, contact with mu-
cous membranes and access to the blood stream. It has a 




The study was done in one private sector laboratory 
with a national network that serves both public and pri-
vate hospitals. Specimens testing positive for Staphylo-
coccus aureus were tested for MRSA using cefoxitin.13  
The sample population included in-patients and outpa-
tients, all ages, both genders, all races. Only one posi-
tive specimen per patient was counted where one patient 
has more than one sampling site [eg. Blood, urine, pus 
swab etc]. 
 
Staphylococcal aureus was recovered from clinical 
specimens (swabs, blood and urine) on McConkey and 
Blood agars incubated at 370C for 24 hours. The cata-
lase test was used for positive cultures, then a Gram 
stain. For in vitro identification of Staphylococcal aure-
us and a latex agglutination test [Bio Rad Pastorex ™ 
Staph-Plus test] was performed. Standard laboratory 
procedures were used for the Kirby-Bauer disk suscep-
tibility test. Cefoxitin (30µg) was used for MRSA test-
ing. Antibiotic susceptibility was performed in Mueller-
Hinton media and incubated for 18 to 24 hours at 37/35 
degrees in the presence of antibiotic discs. For the gly-
copeptides (vancomycin 30µg and teicoplanin 30µg) 
susceptibility testing of Staphylococcus aureus  by disc 
diffusion method was followed by a confirmatory test of 
Minimum Inhibitory Concentration using Etest® (bi-
oMerieux, SA, France). The Etest® consists of a prede-
fined gradient of antibiotic concentration on a plastic 
strip to determine the MIC of the applied antibiotic.14, 15  
 
The following discs were used for susceptibility testing: 
Ampicillin (10µg), Erythromycin (15µg), Rifampicin 
(5µg), Cotrimoxazole (25µg), Clindamycin (2µg), Gen-
tamycin (10µg), Mupirocin (5µg), Fusidic Acid (10µg), 
Telithromycin (15µg), Tetracycline (30µg), Linezolid 
(30µg). The control strain was Staph aureus ATCC 
29213.  
 
The Parirenyatwa and University of Zimbabwe College 
of Health Sciences Joint Research and Ethics Commit-
tee approved the study (JREC/136/13). 
RESULTS 
From June 1st 2013 to May 31st 2014, 407 cases of 
Stapylococcus aureus were reported from the laborato-
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One patient was reported twice, but one month apart 
from different body sites. A second patient was also 
reported twice from separate hospital admissions. There 
were four paediatric patients. Two neonates were posi-
tive for MRSA, one from blood specimen and another 
from sputum in an endotracheal tube tip at extubation. 
The third was pus from a wound in a six year old child 
and the forth was pus but site and source not indicated. 
All specimens had similar antibiotic susceptibility tests. 
The MICs as reported for vancomycin and teicoplanin 
were between <1.0 µg and 2 µg.  The oldest patient was 
83 years old and youngest 13 days. The specimenswere 
pus (19), blood (4), sputum (4), intravenous catheter tip 
(1), surface swab (1) and semen (1). 
 
Figure 1 Age distribution of patients submitting specimens 
 
 
Figure 2 MRSA antibiogram: Percentage of specimens resistant or sensitive to antibiotic [n=30] 
 
The antibiogram showed very mixed susceptibility pat-
tern. The drugs for which there was susceptibility were 
the following, Tetracyline (T), Fusidine (F), Rifampicin 
(R), Vancomycin (V), Teicoplanin (Te), Telithromycin 
(Tt) and Linezolid. The commonest pattern was 
(TFRVTeL) at 13% followed by TFTtVTeL, FVTeL, 
VTeL at 10%. There is some susceptibility to telithro-
mycin (35%), tetracyclines (46%), rifampicin (45%) and 
fusidin (80%) with 100% susceptibility to vancomycin, 
teicoplanin and linezolid. 
 
DISCUSSION 
MRSA appears to have a prevalence of 7% of Staphylo-
coccus aureus cultures in this study. We could not find 
any recent report of MRSA prevalence or of clinical 
cases in Zimbabwe, the last report being in 1991, re-
flecting a possible lack of recognition of its presence.16 
MRSA infection occurred across all age groups. In addi-
tion the MRSA shows resistance to all commonly used 
antimicrobials in Zimbabwe, penicillins, cephalosporins 
and macrolides. This is particularly relevant for clinical 
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antibiogram patterns were diverse with the most com-
mon pattern representing only 13% of cases. A study in 
South Africa showed only slightly better at 18.5% but 
with better response to erythromycin, clindamycin and 
ciprofloxacin.17 
 
This was a small study and a prevalence of 7% may not 
reflect institutional or geographic (national) prevalence. 
There is an urgent need for bigger study and establish-
ment of surveillance system. The MRSA clones in this 
study or in the country are at present unknown and un-
published.  
 
Rifampicin would not be a suitable drug to use because 
it is one of the major anti-tuberculosis drugs. Cost of 
drugs such as vancomycin, teicoplanum and linezolid is 
prohibitive in a very low income country such as Zim-
babwe, and relying on treatment with ever costly drugs 
is not a solution. Prevention and infection control must 
be the first line measures. Antibiotic oversight is re-
quired in Zimbabwe to protect clinicians and patients 
from spread of drug resistance. 
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